PHOENIX, AZ--(Marketwired - Apr 22, 2014) - Insys Therapeutics, Inc. (
Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will host the presentation on Thursday, May 8, 2014 at 2:50 p.m. EDT.
To listen to the audio webcast of this presentation during the event, please visit: www.insysrx.com. A replay of this webcast will be available for 30 days after the initial presentation.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.
Contact Information:
Contact:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com